Haleon PLC (GB:HLN)
LSE:HLN
Want to see GB:HLN full AI Analyst Report?
HLN Stock Chart & Stats
358.60 p
2.70 p(0.71%)
At close: 4:00 PM EST
358.60 p
2.70 p(0.71%)
Day’s Range― - ―
52-Week Range274.40 p - 416.10 p
Previous CloseN/A
Volume4.86M
Average Volume (3M)23.77M
Market Cap
£28.39B
Enterprise Value37.08B
Total Cash (Recent Filing)£676.00M
Total Debt (Recent Filing)£8.54B
Price to Earnings (P/E)28.1
Beta0.43
Next Earnings
Jul 30, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)0.16
Shares Outstanding8,847,261,000
10 Day Avg. Volume25,018,353
30 Day Avg. Volume23,772,072
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£426.67Price Target Upside18.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.21
Revenue Forecast (FY)£11.39B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent free cash flow (~1.7–2.0B) and steady operating cash (~2.1–2.3B) provide durable internal funding for A&P, R&D and debt reduction. This cash profile supports sustained reinvestment into brands and supply‑chain fixes without relying on external financing, enhancing long‑term resilience.
Branded Portfolio StrengthMarket-leading consumer health brands, particularly Oral Health, drive durable competitive advantage via pricing power, retailer placement and consumer loyalty. Strong growth in Sensodyne/Parodontax and targeted A&P reinvestment support sustained category leadership and resilience across retail and e‑commerce channels.
Margin & Productivity GainsMeaningful 220bps margin improvement plus $175–$200m of structural savings reflect successful supply‑chain simplification and cost realignment. Improved OEE and planned ongoing 50–80bps productivity create durable margin tailwinds that can fund growth investments and improve operating leverage over the medium term.
Bears Say
Weak Volume GrowthPersistent low volume expansion (~1% multiyear) signals limited organic adoption beyond price/mix gains. Achieving medium‑term 4%–6% organic targets depends on stronger volume recovery; without it, growth will rely on pricing, portfolio moves or M&A, making long‑term topline durability less certain.
Elevated Leverage & Asset DriftAlthough debt fell in 2025, leverage remains meaningfully above pre‑pandemic levels and total assets have declined since 2022. Elevated leverage constrains strategic flexibility for M&A or buffer against shocks, increasing sensitivity to profit or cash‑flow setbacks over a multi‑quarter horizon.
Seasonality & Channel RiskSignificant exposure to seasonal categories and large U.S. retail channels creates structural top‑line volatility. Repeated weak cold/flu cycles and retailer inventory swings can mute sell‑through and amplify downside in organic sales, making consistent growth more dependent on category and channel timing.
Haleon PLC News
HLN FAQ
What was Haleon PLC’s price range in the past 12 months?
Haleon PLC lowest share price was 274.40 p and its highest was 416.10 p in the past 12 months.
What is Haleon PLC’s market cap?
Haleon PLC’s market cap is £28.39B.
When is Haleon PLC’s upcoming earnings report date?
Haleon PLC’s upcoming earnings report date is Jul 30, 2026 which is in 55 days.
How were Haleon PLC’s earnings last quarter?
Haleon PLC released its earnings results on Feb 25, 2026. The company reported 0.048 p earnings per share for the quarter, beating the consensus estimate of 0.046 p by 0.002 p.
Is Haleon PLC overvalued?
According to Wall Street analysts Haleon PLC’s price is currently Undervalued.
Does Haleon PLC pay dividends?
Haleon PLC pays a Quarterly dividend of 2.2 p which represents an annual dividend yield of 1.51%. See more information on Haleon PLC dividends here
What is Haleon PLC’s EPS estimate?
Haleon PLC’s EPS estimate is 0.05.
How many shares outstanding does Haleon PLC have?
Haleon PLC has 8,847,261,000 shares outstanding.
What happened to Haleon PLC’s price movement after its last earnings report?
Haleon PLC reported an EPS of 0.048 p in its last earnings report, beating expectations of 0.046 p. Following the earnings report the stock price went down -6.852%.
Which hedge fund is a major shareholder of Haleon PLC?
Currently, no hedge funds are holding shares in GB:HLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£426.67 (18.98% Upside)
£426.67 (18.98% Upside)
Blogger Sentiment
Bullish
GB:HLN Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth £2.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.91%
12-Months-Change
Fundamentals
Return on Equity
6.43%
Trailing 12-Months
Asset Growth
-4.91%
Trailing 12-Months
Company Description
Haleon PLC
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
HLN Stock 12 Month Forecast
Average Price Target
426.67 p
▲(18.98% Upside)
Technical Analysis
Allergy Therapeutics
―
Provexis
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---